Search bioRxiv⌕ Search

Biology subjects

Bruns, A. F.

Publications and source records attributed to Bruns, A. F..

2 recordsLinked to original sources

Murine limb ischaemia induces structural and functional remodelling of local and distant bone marrow

Peripheral arterial disease (PAD) can induce bone marrow (BM) ischaemia, although little is known about the implications of this for local and systemic haematopoiesis. We explored the impact of murine unilateral hind-limb ischaemia (HLI) surgery on the structure and function of the ischaemic and non-ischaemic BM, versus control mice without HLI surgery. Abnormal BM hypoxia was present in the ischaemic limb 7-days post-HLI, with normalisation by 28-days. Histological analysis revealed the ischaemic BM to undergo profound vascular remodelling at 7-days that normalised by 61-days, along with a progressive accumulation of BM lipid droplets between 7- and 61-days; no structural changes were observed in the non-ischaemic limb BM. Flow cytometry revealed increased abundance of monocytes and inflammatory monocytes in the non-ischaemic and ischaemic BM 7-days post-HLI, with this persisting at 61-days in the non-ischaemic limb. In both limbs, we observed a progressive decline in the abundance of lineage-Sca-1+c-Kit+ haematopoietic stem cells. RNA-sequencing of BM-derived macrophages (BMDMs) revealed substantial transcriptomic differences between unstimulated control, ischaemic limb and non-ischaemic limb BMDMs. Moreover, there were also substantial transcriptomic differences between lipopolysaccharide-stimulated control and ischaemic limb BMDMs. However, we observed minimal differences in chromatin accessibility of unstimulated BMDMs from the 3 groups. Collectively, our data show that BM ischaemia has transient and sustained structural implications, along with both local and systemic effects on haematopoiesis and myeloid cell function. These findings suggest that PAD may have important consequences for systemic immune responses.

immunology↗

IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy

Glioblastoma (GBM) brain tumours lacking IDH1 mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumours almost always fatally recur. Using RNAseq data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumours, we identified two responder subtypes based on therapy-driven changes in gene expression. In two thirds of patients a specific subset of genes is up-regulated from primary to recurrence (Up responders) and in one third the same genes are down-regulated (Down responders). Characterisation of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms. In Up responders treatment enriches for quiescent proneural GBM stem cells and differentiated neoplastic cells with increased neurotransmitter signalling, whereas Down responders commonly undergo therapy-driven mesenchymal transition. Stratifying GBM tumours by response subtype may lead to more effective treatment. In support of this, modulators of gamma aminobutyric acid (GABA) neurotransmitter signalling differentially sensitise Up and Down responder GBM models to standard treatment in vitro.

cancer biology↗